Literature DB >> 23293410

Multidrug-resistant acinetobacter infection and their susceptibility patterns in a tertiary care hospital.

Kalidas Rit1, Rajdeep Saha.   

Abstract

BACKGROUND: Antibiotic-resistant Acinetobacter nosocomial infection is a leading problem. It acts as an opportunistic pathogen to cause a wide spectrum of infection including nosocomial pneumonia, meningitis, endocarditis, skin and soft tissue infections, urinary tract infection, conjunctivitis, burn wound infection and bacteremia. Multidrug-resistant Acinetobacter infection creates a great problem in hospital setting.
MATERIALS AND METHODS: The clinical specimens obtained from ICU and different surgical and medical wards were investigated using standard microbiological techniques to know the distribution of and their resistant profile. Antimicrobial resistance was studied using the modified Kirby Bauer disk diffusion technique following the CLSI protocol.
RESULTS: Major infections found in different medical wards, surgical wards and ICU were due to Acinetobacter baumannii (74.02%), A. lowfii (14.2%), A. haemolyticus (7.79%), A. junii (3.8%) among Acinetobacter spices. Acinetobacter showed increased resistant against majority of commercially available drugs imipenem (5.2%), meropenem (9.75%), piperacillin-tazobactum (18.2%), netilmicin (16.24%), amikacin (14.29%), ceftazidime (74.1%), gentamicin (70.13%), ofloxacin (42.21%).
CONCLUSION: A. baumannii was found to be associated with UTI, RTI, septicemia, bacteremia, and meningitis and wound infection. A. baumannii displayed higher resistance to more number of antibiotics than other nosocomial pathogens from ICU.

Entities:  

Keywords:  Acinetobacter; antibiotic resistance; nosocomial infection

Year:  2012        PMID: 23293410      PMCID: PMC3531029          DOI: 10.4103/0300-1652.104379

Source DB:  PubMed          Journal:  Niger Med J        ISSN: 0300-1652


INTRODUCTION

Acinetobacter baumannii is an opportunistic pathogen that is frequently involved in outbreaks of infection occurring mostly in intensive care units.1 Members of genus Acinetobacter is gram negative, nonmotile nonspore forming encapsulated coccobacilli belonging to family Neisseriaceae.2 It is an opportunistic pathogen found to be associated with wide spectrum of infection including nosocomial pneumonia, meningitis, endocarditis, skin and soft tissue infections, urinary tract infection, conjunctivitis, burn wound infection and bacteremia posing risk for high mortality.34 Acinetobacter pneumonia generally occurs in patients with diminished host defenses (e.g. alcoholism, tobacco use, diabetes mellitus, and renal failure, underlying pulmonary disease).5–7 Outbreak of Acinetobacter infections is linked to contaminated respiratory equipments, intravascular access devices, bedding materials and transmission via hands of hospital personal.8 It typically colonizes skin and indwelling plastic devices of the hospitalized patients.9 MDR strains of Acinetobacter isolates are a growing problem and have been widely reported.10 Most A. baumannnii are now resistant to ampicillin, carbenicillin, cefotaxime, and chloramphenicol, with some centers reporting up to 91% of nosocomial Acinetobacter resistant to Resistance to tobramycin and amikacin is increasing. Fluoroquinolones, colistin, imipenem, and meropenem may retain activity against nosocomial Acinetobacter.11 Ertapenem, the newest of the carbapenems, has little intrinsic activity against Acinetobacter and should not be used.12 However, the rapid development of significant quinolone resistance in France, aminoglycoside resistance in Germany, and carbapenem resistance in selected regions worldwide raises an important therapeutic problem.1314

MATERIALS AND METHODS

The study was conducted for a period of 2 years. A total 4180 specimens like blood sample, pus, CSF, and other body fluids were subjected to simplified phenotypic identification scheme [Table 1]. Antimicrobial susceptibility testing was done. Presumptive identification of Acinetobacter was made by inoculation on MacConkey agar medium incubated at 37°C. Urine samples were inoculated on CLED also. All nonlactose fermenting members subjected to gram staining, oxidase, catalase, and hanging drop preparation. Acinetobactor are gram-negative bacilli or coccobacilli, oxidase negative, nonmotile, catalase positive. Speciation was done on the basis of glucose oxidation, gelatine liquefaction, haemolysis, growth at 35° and 42°C. Antimicrobial susceptibility testing was done by modified Kirby–Bauer disk diffusion method with imipenem, meropenem, piperacillin-tazobactum, netilmicin, amikacin, ceftazidime, gentamicin, ofloxacin, chloramphenicol disks. The screening test for detection of inducible beta lactamases (IBL), extended spectrum beta lactamases (ESBL), and MBL was done by the disk approximation method and double disk synergy respectively.
Table 1

Identification scheme of Acinetobacter species

Identification scheme of Acinetobacter species

RESULTS

During the period of study from January 2010 to December 2011 a total of 4180 samples were examined from of different age group admitted in various medical wards, surgical wards and ICU. Nonfermenter isolates account for 12% and Acinetobacter isolates account for 4.5% of total organism isolated during the study period. Pseudomonas was the most common nonfermenter (69.44% of total non fermenter isolated). The male: female ratio was 1.5:1. Acinetobacter infection was more common in patients of aged over 40 yrs. Most of these patients had respiratory problems like COPD, bronchial asthma, respiratory failure. Infection in neonates was common in preterm babies. In 87.5% sample growth was monomicrobial. In 12.5% sample growth was polymicrobial. Escherichia coli was the most common associated organism with Acinetobacter in the case of UTI. Staphylococcus aureus was the associated organism in the case of wound infection, cellulitis, and abcess. Acinetobacter was isolated most commonly from surgical ward, medical ward, burn unit, and two isolates were isolated from humidifier ventilator and two isolates from the OT table. The present study shows more strains belonging to Acinetobacter baumanii complex 114 (74.02%) of total Acinetobacter isolates [Table 2]. Other species includes A.lowfii 22 isolates (14.2%), A. haemolyticus 12 (7.79%) isolates, A junni 06 (3.8%) isolates.
Table 2

Different spices of Acinetobacter isolated from clinical samples

Different spices of Acinetobacter isolated from clinical samples One of the striking features of genus Acinetobacter is the ability to develop antibiotic resistant extremely rapid in response to challenge with new antibiotics. In the present study, strains were resistant to imipenem (5.2%), meropenem (9.75%), piperacilin-tazobactum (18.2%), netilmicin (16.24%), amikacin (14.29%), ceftazidime (74.1%), gentamicin (70.13%), ofloxacin ((42.21%), chloramphenicol (92.20%) [Table 3]. IBL and ESBL were detected 10% and 8% isolates of Acinetobacter respectively. The difference in susceptibility pattern was due to environmental factors and different pattern of antimicrobial usage.
Table 3

Sensitivity pattern of Acinetobacter isolate to different antibiotic

Sensitivity pattern of Acinetobacter isolate to different antibiotic

DISCUSSION

Acinetobacter species has emerged as an important pathogen causing life-threatening infections both in community and hospital. Rapid emergence of multidrug-resistant Acinetobacter has further made the situation critical.15 Acinetobacter is found ubiquitously in nature, soil and also in skin as commensal. Infection is commonly transmitted through aerosol. Prior use of broad spectrum antibiotics, cross infection by hand of hospital staff, ventilator machine are all potential risk factors for development of multidrug-resistant Acinetobacter infection in hospital.16 In one study at JIPMER hospital respiratory infections due to Acinetobacter in mechanically ventilated patients in ICU were 44.7%. One recent study revealed that Acinetobacter spp. was responsible for 35% of ventilator associated pneumonia (VAP), making it the most conspicuous and dominant pathogen among all other bacteria encountered in that study.17 In our study, a total of 4180 samples were studied, out of which 504 (12.05%, n=4180) nonfermenters were isolated [Table 4]. Pseudomonas was the most common isolated nonfermenter (69.44%, n=504). Acinetobacter species accounted for (30.55%, n=504) of total nonfermenter and 4.5% of total positive culture. Most of the isolated Acinetobacter species were sensitive to imipenem, meropenem. However, 10% of them were IBL producers and 8% were ESBL producers.
Table 4

Number of other nonfermenter and Acinetobacter isolated from various samples

Number of other nonfermenter and Acinetobacter isolated from various samples

CONCLUSION

In conclusion, multidrug-resistant A. baumannii was responsible for majority of the Acinetobacter infections at our hospital. Injudicious use of antibiotics, mechanical ventilation, cross infection was found to be potential risk factors for development of Acinetobacter infection. During routine microbiological work nonfermenter GNB other than Pseudomonas aeruginosa are not taken seriously and are dismissed as contaminants. But the rate of isolation of Acinetobacter in various studies indicates its role as nosocomial pathogen and also as an agent of community acquired infection. Traditional typing methods like phenotyping and antibiogram typing have advantage over genotyping as they are readily available and cost effective.
  14 in total

1.  Computer keyboards as reservoirs for Acinetobacter baumannii in a burn hospital.

Authors:  A N Neely; M P Maley; G D Warden
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

2.  Six-year prospective study of risk and prognostic factors in patients with nosocomial sepsis caused by Acinetobacter baumannii.

Authors:  J Gómez; E Simarro; V Baños; L Requena; J Ruiz; F García; M Canteras; M Valdés
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-05       Impact factor: 3.267

Review 3.  The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species.

Authors:  David L Paterson
Journal:  Clin Infect Dis       Date:  2006-09-01       Impact factor: 9.079

4.  Community-acquired Acinetobacter pneumonia in the Northern Territory of Australia.

Authors:  N M Anstey; B J Currie; K M Withnall
Journal:  Clin Infect Dis       Date:  1992-01       Impact factor: 9.079

5.  Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii, with carriage in the throat in at-risk groups.

Authors:  Nicholas M Anstey; Bart J Currie; Marilyn Hassell; Didier Palmer; Brian Dwyer; Harald Seifert
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

6.  Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage.

Authors:  V M Manikal; D Landman; G Saurina; E Oydna; H Lal; J Quale
Journal:  Clin Infect Dis       Date:  2000-07-17       Impact factor: 9.079

7.  Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii.

Authors:  X Corbella; A Montero; M Pujol; M A Domínguez; J Ayats; M J Argerich; F Garrigosa; J Ariza; F Gudiol
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

8.  Antimicrobial susceptibility of Acinetobacter species.

Authors:  H Seifert; R Baginski; A Schulze; G Pulverer
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

9.  Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies.

Authors:  R H Glew; R C Moellering; L J Kunz
Journal:  Medicine (Baltimore)       Date:  1977-03       Impact factor: 1.889

10.  Community-acquired Acinetobacter calcoaceticus var anitratus pneumonia.

Authors:  G L Goodhart; E Abrutyn; R Watson; R K Root; J Egert
Journal:  JAMA       Date:  1977-10-03       Impact factor: 56.272

View more
  8 in total

1.  Geographical patterns in antimicrobial resistance of acinetobacter in clinical isolates.

Authors:  Naz Perween; Sonal Sehgal; S Krishna Prakash
Journal:  J Clin Diagn Res       Date:  2014-04-15

2.  Characterization of multiple antibiotic resistance of culturable microorganisms and metagenomic analysis of total microbial diversity of marine fish sold in retail shops in Mumbai, India.

Authors:  Onkar A Naik; Ravindranath Shashidhar; Devashish Rath; Jayant R Bandekar; Archana Rath
Journal:  Environ Sci Pollut Res Int       Date:  2017-12-14       Impact factor: 4.223

3.  Antibiotic Susceptibility of Commensal Bacteria from Human Milk.

Authors:  Po-Wen Chen; Shu-Ying Tseng; Mao-Sheng Huang
Journal:  Curr Microbiol       Date:  2016-02       Impact factor: 2.188

4.  Multidrug-resistant Acinetobacter baumannii infection in intensive care unit patients in a hospital with building construction: is there an association?

Authors:  Sepideh Kamalbeik; Haleh Talaie; Arezou Mahdavinejad; Abdollah Karimi; Alireza Salimi
Journal:  Korean J Anesthesiol       Date:  2014-04-28

5.  Molecular identification of Acinetobacter baumannii isolated from intensive care units and their antimicrobial resistance patterns.

Authors:  Hasan Ghajavand; Bahram Nasr Esfahani; Seyed Asghar Havaei; Sharareh Moghim; Hossein Fazeli
Journal:  Adv Biomed Res       Date:  2015-05-29

6.  Frequency, risk factors, and antibiogram of Acinetobacter species isolated from various clinical samples in a tertiary care hospital in Odisha, India.

Authors:  Muktikesh Dash; Sanghamitra Padhi; Swetlana Pattnaik; Indrani Mohanty; Pooja Misra
Journal:  Avicenna J Med       Date:  2013-10

7.  Occurrence of bla genes encoding carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii from Intensive Care Unit in a tertiary care hospital.

Authors:  Jayanthi Siva Subramaniyan; Jeya Meenakshi Sundaram
Journal:  J Lab Physicians       Date:  2018 Apr-Jun

8.  Identification of genus Acinetobacter: Standardization of in-house PCR and its comparison with conventional phenotypic methods.

Authors:  Sughosh S Kulkarni; Radhika Madalgi; Ganavalli S Ajantha; Raghavendra D Kulkarni
Journal:  J Lab Physicians       Date:  2017 Oct-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.